Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)

• Tania A. Smith,
• Carlos Hoyo-Vadillo,
• Akosua Agyeman Adom,
• Liliana Favari-Perozzi,
• Silke Gastine,
• Hakim-Moulay Dehbi,
• Beatriz Villegas-Lara,
• Eduardo Mateos,
• Yessica Sara Pérez González,
• Maria D. Navarro-Gualito,
• Alejandra S. Cruz-Carbajal,
• Miguel A. Cortes-Vazquez,
• Carolina Bekker-Méndez,
• Charmina Aguirre-Alvarado,
• Gisela Aguirre-Gil,
• Lucero Delgado-Pastelin,
• Andrew Owen,
• David Lowe,
• Joseph Standing,
• Jorge Escobedo

Affiliations

Tania A. Smith

CINVESTAV-IPN

Carlos Hoyo-Vadillo

CINVESTAV-IPN

Akosua Agyeman Adom

ICH-UCL

Liliana Favari-Perozzi

CINVESTAV-IPN

Silke Gastine

ICH-UCL

Hakim-Moulay Dehbi

Clinical Trials Unit, UCL

Beatriz Villegas-Lara

IMSS

Eduardo Mateos

IMSS

Yessica Sara Pérez González

IMSS

Maria D. Navarro-Gualito

IMSS

Alejandra S. Cruz-Carbajal

IMSS

Miguel A. Cortes-Vazquez

IMSS

Carolina Bekker-Méndez

IMSS

Charmina Aguirre-Alvarado

IMSS

Gisela Aguirre-Gil

Hakken Enterprise

Lucero Delgado-Pastelin

Hakken Enterprise

Andrew Owen

University of Liverpool

David Lowe

Division of Infection and Immunity, UCL

Joseph Standing

ICH-UCL

Jorge Escobedo

IMSS